Design Therapeutics: FA Early Data And FDA Discussions Are Promising Catalysts

DSGN’s GeneTAC platform and DT-216P2 for Friedreich’s ataxia: RESTORE-FA data, runway into 2029, and Q4 2026 FDA path catalyst—read now.